Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study.


Journal

Current medical research and opinion
ISSN: 1473-4877
Titre abrégé: Curr Med Res Opin
Pays: England
ID NLM: 0351014

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 16 2 2022
medline: 16 6 2022
entrez: 15 2 2022
Statut: ppublish

Résumé

Post-COVID syndrome (PCS) is a poorly known entity. An underlying chronic, low-grade inflammation (LGI) has been theorized as a pathophysiological mechanism. Available data on biomarkers in PCS show conflicting results. Our aim was to know whether subjects with PCS present higher levels of inflammatory markers, after a mild COVID-19. Analytical cross-sectional study. Cases of mild COVID-19 in a community setting were included. We collected epidemiological data (age, sex, BMI, smoking, comorbidities), variables of the acute COVID-19 (duration, symptoms), and data at 3 months after the acute phase (symptoms and laboratory test). Serum C-reactive protein (CRP), neutrophil and lymphocyte counts, neutrophil/lymphocyte ratio (NLR), lactate dehydrogenase, ferritin, fibrinogen, and D-dimer levels were analysed. LGI was defined as CRP >0.3 and <1.0 mg/dL. A subject was classified as PCS + if presented signs and symptoms >12 weeks after an infection consistent with COVID-19. Five composite indices (C1-C5) were developed, combining the upper ranges of biomarkers distributions. Multivariate analyses were performed. We analysed 121 mild COVID-19 cases (mean age = 45.7 years, 56.2% women). Among the acute symptoms, women presented a higher frequency of fatigue (54.4% vs 30.2%; The data obtained in the present cross-sectional study seems to demonstrate a consistent association between PCS and upper ranges of the neutrophil count, NLR, fibrinogen, and CRP in the LGI range. Furthermore, composite indices appear useful in detecting relationships between slight elevations of biomarkers and PCS, and our study identifies relevant sex differences in symptoms and markers regarding the PCS.

Identifiants

pubmed: 35166141
doi: 10.1080/03007995.2022.2042991
pmc: PMC8935459
doi:

Substances chimiques

Biomarkers 0
Fibrinogen 9001-32-5
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

901-909

Auteurs

Meryam Maamar (M)

Emergency Service. Osakidetza, Servicio Vasco de Salud, Bilbao, País Vasco, Spain.

Arancha Artime (A)

El Llano - Primary Health Care Center, SESPA - Servicio Asturiano de Salud, Gijón Asturias, Spain.

Emilio Pariente (E)

Camargo Interior - Primary Health Care Center, Servicio Cántabro de Salud, Muriedas, Cantabria, Spain.
Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Cantabria, Spain.

Patricia Fierro (P)

Camargo Interior - Primary Health Care Center, Servicio Cántabro de Salud, Muriedas, Cantabria, Spain.

Yolanda Ruiz (Y)

Camargo Interior - Primary Health Care Center, Servicio Cántabro de Salud, Muriedas, Cantabria, Spain.

Silvia Gutiérrez (S)

Camargo Interior - Primary Health Care Center, Servicio Cántabro de Salud, Muriedas, Cantabria, Spain.

Marian Tobalina (M)

Camargo Interior - Primary Health Care Center, Servicio Cántabro de Salud, Muriedas, Cantabria, Spain.

Sara Díaz-Salazar (S)

Camargo Interior - Primary Health Care Center, Servicio Cántabro de Salud, Muriedas, Cantabria, Spain.

Carmen Ramos (C)

Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Cantabria, Spain.
Camargo Costa - Primary Health Care Center, Servicio Cántabro de Salud, Maliaño, Cantabria, Spain.

José M Olmos (JM)

Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Cantabria, Spain.
Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Cantabria, Spain.

José L Hernández (JL)

Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Cantabria, Spain.
Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), Santander, Cantabria, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH